Overview

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Newark Beth Israel Medical Center
Treatments:
Varenicline
Criteria
Inclusion Criteria:

- active smokers presenting to hospital with an acute coronary syndrome

Exclusion Criteria:

- patients with an acute coronary syndrome who are not active smokers